These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23065626)

  • 41. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.
    Beebe-Dimmer JL; Cetin K; Shahinian V; Morgenstern H; Yee C; Schwartz KL; Acquavella J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):70-8. PubMed ID: 22114014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
    Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
    N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
    Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
    Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
    Jayadevappa R; Chhatre S; Malkowicz SB; Parikh RB; Guzzo T; Wein AJ
    JAMA Netw Open; 2019 Jul; 2(7):e196562. PubMed ID: 31268539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
    Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
    Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
    Yang DD; Muralidhar V; Mahal BA; Labe SA; Nezolosky MD; Vastola ME; King MT; Martin NE; Orio PF; Choueiri TK; Trinh QD; Spratt DE; Hoffman KE; Feng FY; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):338-343. PubMed ID: 28463152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.
    Matsushima H; Taguchi T; Kodama S; Okubo N; Saito K; Jabłońska K; Fukumoto S; Matsumoto T
    J Bone Miner Metab; 2024 Mar; 42(2):223-232. PubMed ID: 38493435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
    Baik SH; Kury FSP; McDonald CJ
    J Clin Oncol; 2017 Oct; 35(30):3401-3409. PubMed ID: 28841388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment and management of fracture risk in men with prostate cancer taking androgen deprivation therapy: a retrospective observational primary care database study.
    Huang Q; Brown J; Mitchell C
    Br J Gen Pract; 2024 Jun; 74(suppl 1):. PubMed ID: 38902070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
    Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
    BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer.
    Thomas HR; Chen MH; D'Amico AV; Bennett CL; Kattan MW; Sartor O; Stein K; Nguyen PL
    Clin Genitourin Cancer; 2018 Aug; 16(4):313-317. PubMed ID: 29866496
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).
    Wallander M; Axelsson KF; Lundh D; Lorentzon M
    Osteoporos Int; 2019 Jan; 30(1):115-125. PubMed ID: 30324413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
    Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
    Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
    Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
    Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    Ong WL; Foroudi F; Evans S; Millar J
    BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
    Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
    Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.
    Graham-Steed TR; Soulos PR; Dearing N; Concato J; Tinetti ME; Gross CP
    J Geriatr Oncol; 2014 Oct; 5(4):343-51. PubMed ID: 25240918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.